Literature DB >> 21532814

Perspectives on adherence and persistence with oral medications for cancer treatment.

John Hohneker1, Shilpa Shah-Mehta, Patricia S Brandt.   

Abstract

Ensuring persistence, continuing treatment for the prescribed duration, and adherence-taking medication as prescribed-have been challenges for management of patients with oral cancer and for health care cost containment in real-world settings.

Entities:  

Year:  2011        PMID： 21532814      PMCID： PMC3014515          DOI： 10.1200/JOP.2010.000076

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  22 in total

1.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Authors:  B Fisher; J Dignam; J Bryant; A DeCillis; D L Wickerham; N Wolmark; J Costantino; C Redmond; E R Fisher; D M Bowman; L Deschênes; N V Dimitrov; R G Margolese; A Robidoux; H Shibata; J Terz; A H Paterson; M I Feldman; W Farrar; J Evans; H L Lickley
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

2.  Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.

Authors:  Ann H Partridge; Laura Archer; Alice B Kornblith; Julie Gralow; Debjani Grenier; Edith Perez; Antonio C Wolff; Xiaofei Wang; Helen Kastrissios; Donald Berry; Clifford Hudis; Eric Winer; Hyman Muss
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Dose-response effect of adjuvant chemotherapy in breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

Review 4.  Adherence to therapy with oral antineoplastic agents.

Authors:  Ann H Partridge; Jerry Avorn; Philip S Wang; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

5.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Authors:  Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

6.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Authors:  Ann H Partridge; Philip S Wang; Eric P Winer; Jerry Avorn
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

Authors:  E L Mayer; A H Partridge; L N Harris; R S Gelman; S T Schumer; H J Burstein; E P Winer
Journal:  Breast Cancer Res Treat       Date:  2009-03-18       Impact factor: 4.872

8.  Comparing adherence and persistence across 6 chronic medication classes.

Authors:  Jason Yeaw; Joshua S Benner; John G Walt; Sergey Sian; Daniel B Smith
Journal:  J Manag Care Pharm       Date:  2009 Nov-Dec

9.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

10.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.

Authors:  C McCowan; J Shearer; P T Donnan; J A Dewar; M Crilly; A M Thompson; T P Fahey
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640
View more
  13 in total

1.  High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.

Authors:  Stefan Feiten; Geothy Chakupurakal; Hans Peter Feustel; Michael Maasberg; Burkhard Otremba; Peter Ehscheidt; Manfred Hensel; Richard Hansen; Rudolf Weide
Journal:  Support Care Cancer       Date:  2019-03-11       Impact factor: 3.603

2.  Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.

Authors:  Farah Sahoo; Joshua A Hill; Hu Xie; Wendy Leisenring; Jessica Yi; Sonia Goyal; Louise E Kimball; Ingi Lee; Sachiko Seo; Chris Davis; Stephen A Pergam; Mary E Flowers; Kai-Li Liaw; Leona Holmberg; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-28       Impact factor: 5.742

Review 3.  Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review.

Authors:  M T E Puts; H A Tu; A Tourangeau; D Howell; M Fitch; E Springall; S M H Alibhai
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

Review 4.  Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.

Authors:  Jasem Al-Barrak; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2013-05-25       Impact factor: 3.603

5.  High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis.

Authors:  Elisabetta Xue; Hu Xie; Wendy M Leisenring; Louise E Kimball; Sonia Goyal; Lisa Chung; Rachel Blazevic; Byron Maltez; Anna Edwards; Ann E Dahlberg; Rachel B Salit; Colleen Delaney; Steven A Pergam; Michael Boeckh; Filippo Milano; Joshua A Hill
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

6.  Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies.

Authors:  Marita C Lynagh; Tara Clinton-McHarg; Alix Hall; Rob Sanson-Fisher; William Stevenson; Campbell Tiley; Alessandra Bisquera
Journal:  Exp Hematol Oncol       Date:  2015-06-11

7.  Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data.

Authors:  Adam Amlani; Aalok Kumar; Jenny Y Ruan; Winson Y Cheung
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

8.  Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice.

Authors:  Stefan Feiten; Rudolf Weide; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Hubert Köppler; Christoph van Roye; Jörg Thomalla
Journal:  Springerplus       Date:  2016-03-03

9.  Prevalence and Determinants of Adherence to Oral Adjuvant Endocrine Therapy among Breast Cancer Patients in Singapore.

Authors:  Eskinder Eshetu Ali; Ka Lok Cheung; Chee Ping Lee; Jo Lene Leow; Kevin Yi-Lwern Yap; Lita Chew
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec

10.  The Effect of Structured Education to Patients Receiving Oral Agents for Cancer Treatment on Medication Adherence and Self-efficacy.

Authors:  Gamze Tokdemir; Sultan Kav
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.